Triple-Therapy in Patients With HCV Genotype 3 Who Previously Failed Treatment
Status:
Completed
Trial end date:
2015-07-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to test the potential antiviral efficacy of triple-combination
therapy with Peginterferon α-2b + ribavirin + boceprevir (PRB) in patients with HCV genotype
3 who previously failed Peginterferon α + ribavirin (non-responders or relapsers).